The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Koltsov I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Shchukin I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Fidler M.S.

Pirogov Russian National Research Medical University

Yasamanova A.N.

Pirogov Russian National Research Medical University

Aryasova I.K.

Pirogov Russian National Research Medical University

Boiko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Posterior reversible encephalopathy syndrome in autoimmune disorders

Authors:

Koltsov I.A., Shchukin I.A., Fidler M.S., Yasamanova A.N., Aryasova I.K., Boiko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7‑2): 50‑57

DOI: 10.17116/jnevro202412407250

Views: 861

Downloaded: 2

Buy for 300₽
Contact the author
Table of contents

POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN AUTOIMMUNE DISORDERS
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN AUTOIMMUNE DISORDERS

To cite this article:

Koltsov IA, Shchukin IA, Fidler MS, Yasamanova AN, Aryasova IK, Boiko AN. Posterior reversible encephalopathy syndrome in autoimmune disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7‑2):50‑57. (In Russ.)
https://doi.org/10.17116/jnevro202412407250

 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Close metadata
Recommended articles:
Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and reha­bilitation of patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):56-63
Mortality from cere­brovascular diseases in the Russian Fede­ration before and during the COVID-19 epidemy: regional differences. Russian Journal of Preventive Medi­cine. 2024;(4):12-17
Cere­bral hemo­dynamic diso­rders in patients with schi­zophrenia with concomitant meta­bolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):80-85
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57
Inte­grative asse­ssment of the effe­ctiveness and safety of outpatient use of Pica­milon. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):119-130
Clinical effi­cacy and safety of Pica­milon in patients with progressive chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):71-80
Reco­gnan (citicoline) prescribing in cere­brovascular diseases and type 2 diabetes mellitus patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):23-27
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Inci­dence of diseases of the circulatory system in the working-age popu­lation of the Ural Fede­ral District in 2012—2022. Russian Journal of Preventive Medi­cine. 2025;(1):24-29

Posterior reversible encephalopathy syndrome (PRES) is characterized by nonspecific symptoms, including not only pronounced non-focal and various focal neurological signs but also specific neuroimaging features, including vasogenic edema affecting predominantly the posterior area. PRES usually develops in the setting of acute arterial hypertension. However, it is not uncommon for PRES to develop in non-hypertensive patients, including people with autoimmune disorders (multiple sclerosis, neuromyelitis optica spectrum disorder, etc). PRES could also be due to the toxic effects of drugs or other substances. The pathophysiological mechanisms of PRES include impaired autoregulation of cerebral blood flow due to acute arterial hypertension and toxic endotheliotropic effects of endogenous and exogenous factors.

Keywords:

posterior reversible encephalopathy syndrome
PRES
cerebrovascular diseases
blood-brain barrier

Authors:

Koltsov I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Shchukin I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Fidler M.S.

Pirogov Russian National Research Medical University

Yasamanova A.N.

Pirogov Russian National Research Medical University

Aryasova I.K.

Pirogov Russian National Research Medical University

Boiko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Received:

28.05.2024

Accepted:

29.05.2024

List of references:

  1. Skvortsova VI, Gubskiy LV, Melnikova EA. Posterior reversible encephalopathy syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(5):104-109. (In Russ.).
  2. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. NEJM. 1996;334(8):494-500.  https://doi.org/10.1056/NEJM199602223340803
  3. Lee VH, Wijdicks EFM, Manno EM, et al. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205-210.  https://doi.org/10.1001/archneurol.2007.46
  4. Thavamani A, Umapathi KK, Puliyel M, et al. Epidemiology, Comorbidities, and Outcomes of Posterior Reversible Encephalopathy Syndrome in Children in the United States. Pediatr Neurol. 2020;103:21-26.  https://doi.org/10.1016/j.pediatrneurol.2019.07.007
  5. Raj S, Overby P, Erdfarb A, et al. Posterior reversible encephalopathy syndrome: incidence and associated factors in a pediatric critical care population. Pediatr Neurol. 2013;49(5):335-339.  https://doi.org/10.1016/j.pediatrneurol.2013.06.007
  6. Ansari B, Saadatnia M. Prevalence and Risk Factors of Posterior Reversible Encephalopathy Syndrome in Isfahan, Iran. Adv Biomed Res. 2021;10:53.  https://doi.org/10.4103/abr.abr_243_19
  7. Martynov MYu, Gudkova VV, Koltsova EA, et. al. Arterial Hypertension and Posterior Reversible Encephalopathy Syndrome. Terapiya. 2022;8(9):68-74. (In Russ.). https://doi.org/10.18565/therapy.2022.9.68-74
  8. Aygün BK, Baykuş Y, Berilgen S, et al. Posterior Reversible Encephalopathy Syndrome in severe preeclampsia: case report and literature review. J Turk Ger Gynecol Assoc. 2010;11(4):216-219.  https://doi.org/10.5152/jtgga.2010.41
  9. Ganesh K, Nair RR, Kurian G, et al. Posterior Reversible Encephalopathy Syndrome in Kidney Disease. Kidney Int Rep. 2017;3(2):502-507.  https://doi.org/10.1016/j.ekir.2017.10.017
  10. Musioł K, Waz S, Boroń M, et al. PRES in the course of hemato-oncological treatment in children. Childs Nerv Syst. 2018;34(4):691-699.  https://doi.org/10.1007/s00381-017-3664-y
  11. Bilir ÖA, Dikme G, Malbora B, et al. Posterior Reversible Encephalopathy Syndrome in Childhood Hematological/Oncological Diseases: Multicenter Results. J Pediatr Hematol Oncol. 2021;43(4):e462-e465. https://doi.org/10.1097/MPH.0000000000001965
  12. Racchiusa S, Mormina E, Ax A, Musumeci O, et al. Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2019;40(5):915-922.  https://doi.org/10.1007/s10072-018-3651-4
  13. Gatla N, Annapureddy N, Sequeira W, et al. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2013;19(6):334-340.  https://doi.org/10.1097/RHU.0b013e3182a21ffd
  14. Parikh T, Shifteh K, Lipton ML, et al. Deep Brain Reversible Encephalopathy: Association with Secondary Antiphospholipid Antibody Syndrome. AJNR Am J Neuroradiol. 2007;28(1):76-78. 
  15. Hegde R, Ismail R, Vegunta A, et al. Atypical posterior reversible encephalopathy syndrome in a case of thrombotic thrombocytopenic purpura with Sjogren’s syndrome. Radiol Case Rep. 2021;16(6):1552-1556. https://doi.org/10.1016/j.radcr.2021.03.035
  16. Chow S, Patnana S, Gupta NK. Posterior Reversible Encephalopathy Syndrome in a Patient With Crohn’s Disease on Infliximab. J Clin Gastroenterol. 2016;50(8):687.  https://doi.org/10.1097/MCG.0000000000000557
  17. Navinan MR, Subasinghe CJ, Kandeepan T, et al. Polyarteritis nodosa complicated by posterior reversible encephalopathy syndrome: a case report. BMC Res Notes. 2014;7:89.  https://doi.org/10.1186/1756-0500-7-89
  18. Sharma A, Tyagi A, Singal A. Posterior reversible encephalopathy syndrome in Wegener’s granulomatosis: A rare occurrence. Indian J Anaesth. 2020;64(6):538-539.  https://doi.org/10.4103/ija.IJA_924_19
  19. Machiraju PK, Alex NM, Safinaaz, Sankaran S. Posterior reversible encephalopathy syndrome as the first manifestation of mixed connective tissue disorder: a case report. J Med Case Reports. 2021;15:40.  https://doi.org/10.1186/s13256-021-02678-9
  20. Hussain Awan M, Samreen S, Perveen S, et al. Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis. Rheumatol Immunol Res. 2023;4(2):98-101.  https://doi.org/10.2478/rir-2023-0014
  21. Mastorodemos VC, Ioannidis SG, Papadaki EZ, et al. Posterior Reversible Encephalopathy Syndrome, Multiple Sclerosis and interferon therapy: Association, co-incidence or convoluted interplay? Mult Scler Relat Disord. 2020;45:102356. https://doi.org/10.1016/j.msard.2020.102356
  22. Shima T, Tsujino S, Yamashita K, et al. Neuromyelitis Optica Spectrum Disorder Complicated by Posterior Reversible Encephalopathy Syndrome as an Initial Manifestation. Intern Med. 2020;59(15):1887-1890. https://doi.org/10.2169/internalmedicine.4226-19
  23. de Havenon A, Joos Z, Longenecker L, et al. Posterior reversible encephalopathy syndrome with spinal cord involvement. Neurology. 2014;83(22):2002-2006. https://doi.org/10.1212/WNL.0000000000001026
  24. Anderson RC, Patel V, Sheikh-Bahaei N, et al. Posterior Reversible Encephalopathy Syndrome (PRES):Pathophysiology and Neuro-Imaging. Front Neurol. 2020;11:463.  https://doi.org/10.3389/fneur.2020.00463
  25. Marra A, Vargas M, Striano P, et al. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses. 2014;82(5):619-622.  https://doi.org/10.1016/j.mehy.2014.02.022
  26. Adair TH, Montani JP. Angiogenesis. Morgan & Claypool Life Sciences; 2010. Access. 20.05.24.  https://www.ncbi.nlm.nih.gov/books/NBK53242/
  27. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242-248.  https://doi.org/10.1038/35025215
  28. Felcht M, Luck R, Schering A, et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 2012;122(6):1991-2005. https://doi.org/10.1172/JCI58832
  29. Blanco R, Gerhardt H. VEGF and Notch in Tip and Stalk Cell Selection. Cold Spring Harb Perspect Med. 2013;3(1):a006569. https://doi.org/10.1101/cshperspect.a006569
  30. Dvorak AM, Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem. 2001;49(4):419-432.  https://doi.org/10.1177/002215540104900401
  31. Brindle NPJ, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res. 2006;98(8):1014-1023. https://doi.org/10.1161/01.RES.0000218275.54089.12
  32. Lenting PJ, Casari C, Christophe OD, et al. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012;10(12):2428-2437. https://doi.org/10.1111/jth.12008
  33. Rauch A, Wohner N, Christophe OD, et al. On the Versatility of von Willebrand Factor. Mediterr J Hematol Infect Dis. 2013;5(1):e2013046. https://doi.org/10.4084/MJHID.2013.046
  34. Romani de Wit T, Rondaij MG, Hordijk PL, et al. Real-time imaging of the dynamics and secretory behavior of Weibel-Palade bodies. Arterioscler Thromb Vasc Biol. 2003;23(5):755-761.  https://doi.org/10.1161/01.ATV.0000069847.72001.E8
  35. Rondaij MG, Bierings R, Kragt A, et al. Dynamics and Plasticity of Weibel-Palade Bodies in Endothelial Cells. Arterioscler Thromb Vasc Biol. 2006;26(5):1002-1007. https://doi.org/10.1161/01.ATV.0000209501.56852.6c
  36. van Agtmaal EL, Bierings R, Dragt BS et al. The Shear Stress-Induced Transcription Factor KLF2 Affects Dynamics and Angiopoietin-2 Content of Weibel-Palade Bodies. Plos One. 2012;7(6):e38399. https://doi.org/10.1371/journal.pone.0038399
  37. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005;118(4):771-780.  https://doi.org/10.1242/jcs.01653
  38. Koltsov IA, Shchukin IA, Chubykin VI, Fidler MS. Neuroinflammation and Thromboinflammation in Cerebrovascular Disease and Vascular Cognitive Impairment. Terapiya. 2022;8(9):61-66. (In Russ.). https://doi.org/10.18565/therapy.2022.9.75-81
  39. Koltsov IA, Martynov MYu, Yasamanova AN, et al. Influence of von Willebrand factor on common pathophysiological mechanisms of cerebrovascular diseases and multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;1 3 (1S):62-68. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1S-62-68
  40. Lee SW, Kim WJ, Jun HO, et al. Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2. Int J Mol Med. 2009;23(2):279-284. 
  41. Gurnik S, Devraj K, Macas J, et al. Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling. Acta Neuropathol (Berl). 2016;131(5):753-773.  https://doi.org/10.1007/s00401-016-1551-3
  42. Solar P, Hendrych M, Barak M, et al. Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions. Front Cell Neurosci. 2022;16:34-39.  https://doi.org/10.3389/fncel.2022.922181
  43. Van Hulle C, Ince S, Okonkwo OC, et al. Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease. Transl Psychiatry. 2024;14 (1):1-8.  https://doi.org/10.1038/s41398-023-02706-w
  44. Gewirtz AN, Gao V, Parauda SC, et al. Posterior Reversible Encephalopathy Syndrome. Curr Pain Headache Rep. 2021;25(3):19.  https://doi.org/10.1007/s11916-020-00932-1
  45. Proescholdt MA, Jacobson S, Tresser N, et al. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol. 2002;61(10):914-925.  https://doi.org/10.1093/jnen/61.10.914
  46. Amini Harandi A, Siavoshi F, Shirzadeh Barough S, et al. Vascular Endothelial Growth Factor as a Predictive and Prognostic Biomarker for Multiple Sclerosis. Neuroimmunomodulation. 2022;29(4):476-485.  https://doi.org/10.1159/000525600
  47. Largeau B, Le Tilly O, Sautenet B, et al. Arginine Vasopressin and Posterior Reversible Encephalopathy Syndrome Pathophysiology: the Missing Link? Mol Neurobiol. 2019;56(10):6792-6806. https://doi.org/10.1007/s12035-019-1553-y
  48. Largeau B, Bergeron S, Auger F. et al., Experimental Models of Posterior Reversible Encephalopathy Syndrome: A Review From Pathophysiology to Therapeutic Targets. Stroke. 2024;55(2):484-493.  https://doi.org/10.1161/STROKEAHA.123.044533
  49. McKinney AM, Sarikaya B, Gustafson C, et al. Detection of microhemorrhage in posterior reversible encephalopathy syndrome using susceptibility-weighted imaging. AJNR Am J Neuroradiol. 2012;33(5):896-903.  https://doi.org/10.3174/ajnr.A2886
  50. Appiani F, Claverie CS, Klein FR. Posterior Reversible Leukoencephalopathy With Hemorrhagic Features: A Case Series. Cureus. 2023;15(11):e49587. https://doi.org/10.7759/cureus.49587
  51. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. Am J Neuroradiol. 2008;29(6):1036-1042. https://doi.org/10.3174/ajnr.A0928
  52. Pilato F, Distefano M, Calandrelli R. Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome: Clinical and Radiological Considerations. Front Neurol. 2020;11:34-37.  https://doi.org/10.3389/fneur.2020.00034
  53. Triplett JD, Kutlubaev MA, Kermode AG, et al. Posterior reversible encephalopathy syndrome (PRES):diagnosis and management. Pract Neurol. 2022;22(3):183-189.  https://doi.org/10.1136/practneurol-2021-003194
  54. Morrow SA, Rana R, Lee D, et al. Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse. Case Rep Neurol Med. 2015;12:325657. https://doi.org/10.1155/2015/325657
  55. Dietz N, Mufti Z, Yousaf M, et al. Acute posterior reversible encephalopathy syndrome (PRES) in setting of interferon-beta use: case presentation with reduction of edema in 72 h after cessation of interferon-beta therapy with sub-clinical inflammation. BMC Neurol. 2021;21(1):445.  https://doi.org/10.1186/s12883-021-02471-7
  56. Lindå H, von Heijne A. A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis. Front Neurol. 2015;6:39.  https://doi.org/10.3389/fneur.2015.00039
  57. Décard BF, Haghikia A, Tönnes C, et al. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy. Mult Scler Houndmills Basingstoke Engl. 2013;19 (2):249-251.  https://doi.org/10.1177/1352458512448268
  58. Magaña SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009;72(8):712-717.  https://doi.org/10.1212/01.wnl.0000343001.36493.ae
  59. Matiello M, Muralidharan R, Sun D, et al. Posterior reversible encephalopathy syndrome is not associated with mutations in aquaporin-4. Neurol Genet. 2015;1(2):e 19.  https://doi.org/10.1212/NXG.0000000000000013
  60. Corbett J, Bhuta S, Prain K, et al. PRES-like presentation in MOG antibody-related demyelination (MARD). J Clin Neurosci Off J Neurosurg Soc Australas. 2020;72:453-455.  https://doi.org/10.1016/j.jocn.2020.01.034
  61. Zou LP, Liu LY, Li H, et al. Establishment and utility assessment of posterior reversible encephalopathy syndrome early warning scoring (PEWS) scale establishment and utility assessment of PEWS scale. BMC Neurol. 2019;19(1):30.  https://doi.org/10.1186/s12883-019-1247-0
  62. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925.  https://doi.org/10.1016/S1474-4422(15)00111-8
  63. Hinduja A. Posterior Reversible Encephalopathy Syndrome: Clinical Features and Outcome. Front Neurol. 2020;11:71.  https://doi.org/10.3389/fneur.2020.00071
  64. Legriel S, Schraub O, Azoulay E, et al. Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS). Determinants of Recovery from Severe Posterior Reversible Encephalopathy Syndrome. PLoS ONE. 2012;7(9):e44534. https://doi.org/10.1371/journal.pone.0044534
  65. Liu L, Dai D, Cao F, et al. Posterior reversible encephalopathy syndrome with spinal cord involvement but without hemisphere lesions. Medicine (Baltimore). 2019;98(2):e13649. https://doi.org/10.1097/MD.0000000000013649
  66. Hugonnet E, Da Ines D, Boby H, et al. Posterior reversible encephalopathy syndrome (PRES):features on CT and MR imaging. Diagn Interv Imaging. 2013;94(1):45-52.  https://doi.org/10.1016/j.diii.2012.02.005
  67. Burdette JH, Elster AD, Ricci PE. Acute cerebral infarction: quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images. Radiology. 1999;212(2):333-339.  https://doi.org/10.1148/radiology.212.2.r99au36333
  68. Parauda SC, Zhang C, Salehi Omran S, et al. Risk of Stroke After Posterior Reversible Encephalopathy Syndrome. Stroke. 2022;53(11):3313-3319. https://doi.org/10.1161/STROKEAHA.122.038673
  69. Fazeli S, Noorbakhsh A, Imbesi SG, et al. Cerebral perfusion in posterior reversible encephalopathy syndrome measured with arterial spin labeling MRI. NeuroImage Clin. 2022;35:103017. https://doi.org/10.1016/j.nicl.2022.103017
  70. Hedna VS, Stead LG, Bidari S, et al. Posterior reversible encephalopathy syndrome (PRES) and CT perfusion changes. Int J Emerg Med. 2012;5:12.  https://doi.org/10.1186/1865-1380-5-12
  71. Cho S, Lee MJ, Chung CS. Effect of Nimodipine Treatment on the Clinical Course of Reversible Cerebral Vasoconstriction Syndrome. Front Neurol. 2019;10:644.  https://doi.org/10.3389/fneur.2019.00644
  72. Yıldırım Eryılmaz N, Ocakoglu G. Comparison of magnesium sulfate and mannitol in treatment of eclamptic women with posterior reversible encephalopathy syndrome. Arch Gynecol Obstet. 2012;286(2):287-293.  https://doi.org/10.1007/s00404-012-2268-8
  73. Parikh NS, Schweitzer AD, Young RJ, et al. Corticosteroid Therapy and Severity of Vasogenic Edema in Posterior Reversible Encephalopathy Syndrome. J Neurol Sci. 2017;380:11-15.  https://doi.org/10.1016/j.jns.2017.06.044
  74. Shibata T, Hashimoto N, Mase M. Intracranial hemorrhage in posterior reversible encephalopathy syndrome due to corticosteroid pulse therapy. Brain Disord. 2022;7:100040. https://doi.org/10.1016/j.dscb.2022.100040
  75. Meyer M, Niemöller U, Stein T, et al. Positive Effect of Steroids in Posterior Reversible Encephalopathy Syndrome. Case Rep Neurol. 2019;11(2):173-177.  https://doi.org/10.1159/000500410
  76. Arslan Zİ, Turna CK, Özerdem ÇY, et al. Treatment of Posterior Reversible Encephalopathy Syndrome that Occurred in a Patient with Systemic Lupus Erythematosus by Plasmapheresis. Turk J Anaesthesiol Reanim. 2015;43(4):291-294.  https://doi.org/10.5152/TJAR.2015.13540
  77. Demirel İ, Kavak BS, Özer AB, et al. An intensive care approach to posterior reversible encephalopathy syndrome (PRES):An analysis of 7 cases. J Turk Ger Gynecol Assoc. 2014;15(4):217-221.  https://doi.org/10.5152/jtgga.2014.14072
  78. Shadman J, Sadeghian N, Moradi A, et al. Magnesium sulfate protects blood-brain barrier integrity and reduces brain edema after acute ischemic stroke in rats. Metab Brain Dis. 2019;34(4):1221-1229. https://doi.org/10.1007/s11011-019-00419-y
  79. Seitz A, Parauda SC, Salehi Omran Set al. Long-term risk of seizure after posterior reversible encephalopathy syndrome. Ann Clin Transl Neurol. 2023;10(4):610-618.  https://doi.org/10.1002/acn3.51748
  80. Receivd 28.05.2024 

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.